entertainment -WSS

entertainment

author：leisure time 2025-09-29 19:59:06 - browse：61265

STAT's Megan Molteni speaks with Feng Zhang in New York on March 21, 2024 — Scientist Feng Zhang, right, is interviewed by reporter Megan Molteni at STAT's Breakthrough Summit East. STAT

When the first biotech companies emerged to capitalize on the revolutionary genome-editing technology CRISPR, Editas Medicine seemed like the pacesetter. It locked up some of the crucial IP, and had behind it the pioneering scientist Feng Zhang of the Broad Institute as one of its founders.

But now, a decade later, Editas is seen as lagging behind its peers. CRISPR Therapeutics, in partnership with Vertex Pharmaceuticals, won the race to get the first CRISPR-based medicine across the finish line. Intellia Therapeutics was the first to show that CRISPR editing could be performed inside the body. Editas, meanwhile, has seen a revolving door among its executives.

So what happened?

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Why Eli Lilly’s earnings didn’t quite live up to the hype

WSS

The drug industry has found itself all alone in Washington

ACIP vaccine advisory panel sees its vacancies filled

Resistance to opioid

Too many hospitalized Covid

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Precocious puberty in girls comes with mental health risks

Wikipedia

entertainment

focus

Trump demands the U.S. pay no more for drugs than other countries … again

STAT Boddities: What happens to the brain when we get scared?

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Websites selling Wegovy, Zepbound ingredients targeted by FDA

The high cost of giving birth even with insurance

Readout Newsletter: Amylyx, Aurinia, and IQVIA

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Here’s what’s in the FDA plan to include pregnant women in clinical trials

The cancer drug shortage isn’t new — and neither are the solutions

ACIP vaccine advisory panel sees its vacancies filled

leisure time

Amylyx ALS drug fails large clinical trial

Amylyx ALS drug fails large clinical trial

How to bring more disabled researchers into academia

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Readout Newsletter: Amylyx, Aurinia, and IQVIA

Too many hospitalized Covid

hotspot

hotspot

leisure time

knowledge